Daiichi Sankyo Company, Limited · TSE:4568
Daiichi Sankyo — Investor Presentation (July 2006)
12 slides from Daiichi Sankyo's investor presentation, Jul 31, 2006
Slide 1: Report to Shareholders
Report to Shareholders Daiichi-Sankyo IR Report 2005 {or the Fist Term Ending March 31, 2006 (September 28, 2005 to March 31, 2006) DAIICHI SANKYO CO., LTD.
Slide 2: Goals of the DAIICHI SANKYO Group
Goals of the DAIICHI SANKYO Group By targeting the global marketplace and maximizing its strengths and competitive advantage, DAIICHI SANKYO aims to be a “Global Pharma Innovator Originating in Japan” I, Daiichi-Sankyo Integration synergy Boundless possibilities G+ By the completion of the merger pr
Slide 3: Innovative R&D
Innovative R&D R&D spending L Qeition ¥143.9 sition id Fy2004 F209 (tae Ta) We intend to secure a position of leadership by developing promising candidate drugs in major ‘therapeutic areas. Raising the pace of development through a concentration of resources, we plan to boost R&D spending aggressive
Slide 4: Slide 4
Slide 5: Merger integration timeline
2005 2006 8 9 m@ | im | 2 1 2 3 4 5s Ha 7 8 9 DAIICHI SANKYO COMPANY, LTD. established Planning phase Design phase Transitional preparati {p> Sankyo Company, Daiichi Pharmaceutical Limited Co., Ltd. Domestic sales operations Domestic sales operations hi Sankyo Co., Ltd. } ‘eNovenber 205: Colaorave r
Slide 6: Trends in Major Products
Trends in Major Products Top Three Products The DAIICHI SANKYO prescription drug portfolio ranks among the finest in the industry. Many products in the lineup are strong sellers and highly competitive. The drugs positioned as our top products are expected to play particularly important roles in our
Slide 7: Cravit
Cravit ® The broad-spectrum oral antibacterial Cravit ® (generic name: levofloxacin) is an orally active antibiotic of the new quinolone type that is widely recognized as offering superior efficacy along with excellent safety characteristics. Since its launch in Japan in 1993, its powerful antibacte
Slide 8: Sales breakdown by category
Other "ions tye") 15.3% crs12) Prescription drugs in Japan 46.6:
Slide 9: Consolidated Balance Sheet (Summary)
Consolidated Balance Sheet (Summary) (Millions of yen) March 31, 2006 ASSETS Current assets: 958,483 Cash and time deposits 223,979 Trade notes and accounts receivable 240,173 Marketable securities 274,510 Other current assets 220,419 Allowance for doubtful accounts (599 ) Non-current assets: 637,64
Slide 10: Sankyo Group results for the year ended March 31, 2006
In the year ended March 31, 2006, the Sankyo Group posted consolidated net sales of ¥579,949 million (a decline by 1.3% compared with the previous year), operating income of ¥78,335 million (a decrease by 7.8%), ordinary income of ¥82,164 million (a decrease by 0.4%) and net income of ¥50,627 millio
Slide 11: Daiichi Group results for the year
The Daiichi Group focused its marketing efforts on expanding markets for its products by promoting the proper use of drugs through the provision of information related to the efficacy and safety of its products. Higher revenue from domestic sales of prescription drugs, an increase in bulk exports of
Slide 12: Major Shareholders
Major Shareholders Shareholder’s name No. of shares held Shareholding ratio (%) The Master Trust of Japan, Ltd. (Trust Account) 55,883,800 7.60 Japan Trustee Services Bank, Ltd. (Trustee Account) 48,316,400 6.57 Nippon Life Insurance Company 41,839,182 5.69 The Chase Manhattan Bank NA London SL Omni
Daiichi Sankyo Company — Investor Presentation (July 2006) on 6ix